Determinants of lack of atherosclerosis progression in adult patients with elevated lipoprotein (a): results from the STAR-Lp(a) study

Bożena Sosnowska[1], Ibadete Bytyci[2,3,4], Joanna Lewek[1,5], Agata Bielecka-Dabrowa[1,5], Monika Burzyńska[6,7], Piotr Jankowski[6,8], Michal Chudzik[6,9], Maciej Banach[1,5,10,11]

[1]Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland
[2]Clinic of Cardiology, University Clinical Centre of Kosovo, Prishtina, Kosovo
[3]Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
[4]Medical Faculty, University of Prishtina, Prishtina, Kosovo
[5]Department of Cardiology and Adult Congenital Heart Diseases, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland
[6]Department of Internal Medicine and Geriatric Cardiology, Medical Centre for Postgraduate Education, Warsaw, Poland
[7]Department of Epidemiology and Biostatistics, Division of Social and Preventive Medicine, Medical University of Lodz, Lodz, Poland
[8]Department of Epidemiology and Health Promotion, Centre of Postgraduate, School of Public Health, Warsaw, Poland
[9]Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Lodz, Poland
[10]Faculty of Medicine, the John Paul II Catholic University of Lublin (KUL), Lublin, Poland
[11]Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Corresponding author:
Prof. Maciej Banach,
MD, PhD, FNLA,
FAHA, FESC
Faculty of Medicine
The John Paul II
Catholic University
of Lublin
Konstantynów 1I
20-708 Lublin, Poland
E-mail: maciej.banach@kul.pl

Abstract

Introduction: Lipoprotein (a) (Lp(a)) is a largely genetically determined (70–90%) independent risk factor for cardiovascular disease (CVD). However, clinicians often encounter adults/elder adults with elevated Lp(a), who are otherwise healthy and asymptomatic for atherosclerosis. We aimed to identify additional risk factors and conditions, apart from elevated Lp(a), which lead to atherosclerosis progression and CVD, and whether any protective factors mitigate Lp(a)-related risk.

Material and methods: In the STAR (Specialist Care Patients) Lp(a) study, we prospectively enrolled 2,594 consecutive patients aged over 50 years, who had elevated Lp(a), referred to two outpatient cardiology clinics. These patients were either healthy, or had established CVD or three or more cardiovascular risk factors. Lp(a) concentration was measured by enzyme-linked immunosorbent assay.

Results: Among adults > 50 years with Lp(a) ≥ 30 mg/dl (75 nmol/l) (mean Lp(a), 65.4 vs. 72.7 mg/dl, $p = 0.118$), healthy individuals and patients differed significantly in mean age (62.8 vs. 69.6 years, $p < 0.001$), body mass index (BMI) and prevalence of overweight/ obesity (16.0% vs. 32.7%, $p = 0.001$), mean hsCRP (2.12 vs. 2.35 mg/l, $p = 0.007$), dyslipidemia, mean glucose and HbA_{1c} levels (5.44% vs. 5.86%, $p < 0.001$), and coronary artery calcium (CAC) scores (43.1 vs. 339.9, $p < 0.001$). In multivariable analysis, the independent predictors of increased CAC in healthy individuals were gender and non-HDL-C, while in patients, the independent predictors were non-HDL-C and age. Correlation analysis showed that in healthy individuals, CAC correlated

Bożena Sosnowska, Ibadete Bytyci, Joanna Lewek, Agata Bielecka-Dabrowa, Monika Burzyńska, Piotr Jankowski, Michal Chudzik, Maciej Banach

with gender and non-HDL-C, while in patients, CAC correlated with age, gender, non-HDL-C, HbA1c, and Lp(a). Comparing sub-groups with Lp(a) > 50 mg/dl (125 nmol/l) (mean age: 62.3 vs. 69.2 years, $p < 0.001$; female: 77.8% vs. 68.5%, $p = 0.021$; mean Lp(a) : 87.8 vs. 88.8 mg/dl, $p = 0.838$), the independent predictors of CAC in healthy individuals were elevated hsCRP and gender, whereas in patients, they were age and Lp(a). Correlation analysis confirmed that Lp(a) was significantly associated with CAC in patients only, and LDL-C and hsCRP correlated with CAC in patients only.

Conclusions: In adults > 50 years with elevated Lp(a), Lp(a) – related risk of atherosclerosis progression can be substantially mitigated by addressing modifiable CVD risk factors, such as obesity, diabetes, inflammation, and dyslipidemia, preferably by early preventive measures. In our study cohort, Lp(a) was independently associated with atherosclerosis progression in the patient group only.

Key words: risk stratification, lipoprotein (a), cardiovascular disease, prevention.

Introduction

Lipoprotein (a) (Lp(a)) is a specific lipoprotein composed of an low-density lipoprotein (LDL)-like particle and apolipoprotein (a) (apo (a)), structure of which resembles that of plasminogen [1]. The unique properties of Lp(a), particularly its capacity to transport oxidized phospholipids (Ox-PLs), contributes to a distinctive risk profile for atherosclerotic cardiovascular disease (ASCVD), characterized by pro-atherogenic, pro-inflammatory, and anti-fibrinolytic features [2–4]. Approximately 90% of plasma Lp(a) concentrations are determined by genetic variation in the LPA gene [5]. Robust evidence supports Lp(a) as a genetically regulated, independent risk factor for various cardiovascular conditions, including myocardial infarction, aortic valve stenosis, peripheral artery disease, heart failure, and stroke [3, 6–10].

Genetic and epidemiological evidence further emphasize the potency of Lp(a) as a cardiovascular disease (CVD) risk factor. Data from the UK Biobank indicate that Lp(a) particles are over six times more strongly associated with CVD risk than LDL particles, a finding consistent with the results from other epidemiological studies [11, 12]. However, in the majority of patients, LDL particles are present in far greater numbers than Lp(a) particles [13]. Moreover, Lp(a) appears to have a more significant impact on the development and progression of atheroma, especially in later stages of disease, while LDL-C exerts its influence steadily across all phases of atherogenesis [14, 15].

Despite extensive research on Lp(a), many aspects of its biological function and contribution to disease remain unclear [16]. While Lp(a) levels are linearly correlated with CVD risk and recognized as an independent predictor of adverse outcomes, epidemiological evidence highlights significant inter-individual variability, suggesting that a substantial proportion of individuals with elevated Lp(a) may never develop cardiovascular disease, even at advanced age [17]. Recent long-term data from Ridker *et al.* [18] demonstrated that, during a 30-year follow-up of over 27,000 initially healthy women (mean baseline age of 54.7

years), less than 15% of those with the highest quintile of Lp(a) levels experienced cardiovascular events, underscoring the heterogeneity in clinical outcomes despite elevated Lp(a) [18]. In the context of secondary prevention, most individuals (58.8%) with Lp(a) levels exceeding 150 nmol/l (> 60 mg/dl) remained free of further cardiovascular events in a median follow-up of 4.7 years [19]. These findings indicate the need for improved risk stratification among patients with elevated Lp(a) by exploring modulating factors, such as systemic inflammation, lipid metabolism, and other recognized CVD risk factors, which may determine why elevated Lp(a) leads to clinical events in some individuals but not in others.

Therefore, in this analysis, we aimed to comprehensively investigate which cardiovascular risk factors and concomitant conditions, apart from elevated Lp(a) levels, are associated with atherosclerosis progression and the diagnosis of cardiovascular disease. Furthermore, the study sought to identify potential protective factors, which may decrease the CVD risk attributed to increased Lp(a) concentrations, aiming to better understand the interplay between Lp(a) and other clinical or biochemical determinants in individuals over 50 years of age.

Material and methods

Study population and design

This was a cross-sectional sub-analysis of the prospective STAR (Specialist Care Patients)-Lp(a) study, which included 2,594 consecutive patients referred to two outpatient cardiology clinics [20]. For the present analysis, we selected individuals aged over 50 years with elevated Lp(a) levels (≥ 30 mg/dl), regardless of their cardiovascular risk status. This sub-group comprised individuals diagnosed with cardiovascular disease and those with at least three classical cardiovascular risk factors (CRFs), such as arterial hypertension, diabetes mellitus, dyslipidemia, smoking, and obesity, whereas individuals without CVD diagnosis or any CRFs were included in a healthy comparison group. The cutoff value of 50 years for age was chosen based on

data availability, as there was insufficient information on healthy individuals in older age group (i.e., > 60–65 years) obtainable for enrollment.

To assess the impact of additional risk and protective factors in the context of elevated Lp(a), participants with Lp(a) level ≥ 30 mg/dl (≥ 75 nmol/l) were first divided into a wider group. Within this population, a distinct high-risk sub-group with Lp(a) > 50 mg/dl was subsequently identified and analyzed separately.

Within each Lp(a) category, participants over 50 years of age were further stratified into two groups: Group 1: Patient group consisting of individuals with established CVD or ≥ 3 cardiovascular risk factors; and group 2: Healthy group including patients without CVD diagnosis or any evident CRFs, despite elevated Lp(a). This classification enabled analysis of determinants, which may contribute to or protect against atherosclerosis progression in the presence of elevated Lp(a) levels.

Lipoprotein(a) and other variables analyses

The following quantitative variables were analyzed: age, body mass index (BMI), total cholesterol (TC), LDL-C, high-density lipoprotein cholesterol (HDL-C), non-HDL cholesterol, triglycerides (TG), TG/HDL-C ratio, fasting blood glucose (FBG), glycated hemoglobin A_{1c} (HbA$_{1c}$), homocysteine, creatinine, estimated glomerular filtration rate (eGFR), thyroid-stimulating hormone (TSH), systolic and diastolic blood pressure, and heart rate. Qualitative variables, including sex and comorbidities (i.e., hypertension, hyperlipidemia, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, sleep disorders, and atrial fibrillation), were defined according to current guidelines described in detail elsewhere [20, 21]. Lp(a) concentration was determined using an enzyme-linked immunosorbent assay.

Statistical analysis

Data were summarized as frequencies and percentages for categorical variables, and as mean ± standard deviation or median for continuous variables, as appropriate. Continuous variables were compared with two-tailed Student's *t*-test, and for categorical variables, χ^2 test was used. Fisher's exact test was applied where the expected cell counts were low. Correlations between continuous variables were assessed using Pearson's correlation coefficient in normally distributed data, while Spearman's rank correlation coefficient was employed if normality assumptions were not met. Predictors of increasing calcium scores were evaluated using linear regression in all participants as well as separately in groups of patients and healthy individuals. Differences between groups were additionally compared using log-rank test. A *p*-value

< 0.05 (two-tailed) was considered statistically significant. Statistical analyses were performed using SPSS software, version 26.0 (IBM Corp., Armonk, NY, USA) and Stata software (StataNow version 18.5, StataCorp, College Station, TX, USA).

Results

Characteristic of healthy individuals and patients with Lp(a) ≥ 30 mg/dl

The analysis finally included 50 healthy individuals and 295 patients. Patients were significantly older than the healthy group (69.6 ±8.7 vs. 62.8 ±8.7 years, *p* < 0.001). The proportion of females did not differ significantly between the groups (71.9% vs. 78.0%, *p* = 0.236). Patients with a higher mean BMI (28.5 ±5.1 vs. 26.9 ±4.5 kg/m², *p* = 0.033) had an increased prevalence of overweight (75.2% vs. 68.0%, *p* = 0.012) and obesity (32.7% vs. 16.0%, *p* = 0.001). The mean Lp(a) concentrations did not differ significantly between healthy individuals and patients, with values of 65.4 and 72.7 mg/dl, respectively (*p* = 0.118) (Table I). The prevalence of arterial hypertension reached 79.7%, diabetes mellitus was present in 32.2% of patients, and dyslipidemia in 33.2%. Additionally, 16.9% of patients had a history of coronary artery disease (CAD), and 9.2% had experienced a previous stroke. Lipid-lowering therapy (LLT) was commonly used among patients: 67.8% were treated with statins, while a small percentage received ezetimibe (0.8%), combination therapy (1.5%), or fibrates (1.0%). In terms of laboratory results, patients had significantly higher hsCRP levels (2.35 ±4.7 vs. 2.12 ±2.4 mg/l, *p* = 0.007), glucose levels (104.8 ±31 vs. 91.8 ±16 mg/dl, *p* < 0.001), and HbA$_{1c}$ levels (5.86 ±0.8% vs. 5.44 ±0.5%, *p* < 0.001). LDL-C (103.6 ±43 vs. 140.5 ±34 mg/dl), total cholesterol, and non-HDL-C were significantly lower in the patient group (*p* < 0.001), reflecting pharmacologic treatment (Table I).

There was a significantly higher CAC score among the patient group compared to the healthy group (339.9 ±543 vs. 43.1 ±99, *p* < 0.001), with fewer individuals scoring 0 (63.1% vs. 82.0%, *p* = 0.001), and more with CAC score ≥ 100 (24.7% vs. 4.0%, *p* < 0.001). Echocardiographic indices demonstrated a trend towards lower left ventricular ejection fraction (LVEF) in the patient group (57.4 ±5.8% vs. 59.8 ±4.4%, *p* = 0.051), and significantly lower tricuspid annulus plane systolic excursion (TAPSE) (2.49 ±0.25 vs. 2.64 ±0.26 cm, *p* = 0.013) (Table I).

Linear regression analysis of 50+ healthy individuals and patients with Lp(a) ≥ 30 mg/dl

A linear regression analysis was conducted to evaluate the association between selected clinical

Bożena Sosnowska, Ibadete Bytyci, Joanna Lewek, Agata Bielecka-Dabrowa, Monika Burzyńska, Piotr Jankowski, Michal Chudzik, Maciej Banach

Table I. Demographic, laboratory, and imaging indices among healthy individuals and patients aged > 50 years and Lp(a) ≥ 30 mg/dl

Variable	Healthy	Patients	P-value
	(n = 50)	(n = 295)	
Demographic and clinical indices			
Age [years]	62.8 ±8.7	69.6 ±8.7	< 0.001
Female gender (%)	78.0	71.9	0.236
BMI [kg/m²]	26.9 ±4.5	28.5 ±5.1	0.033
Overweight (%)	68.0	75.2	0.012
Obese (%)	16.0	32.7	0.001
HR [bpm]	74.9 ±10	73.5 ±11	0.227
Sinus rhythm (%)	100.0	96.3	0.621
Cardiovascular risk factors			
AH (%)	–	79.7	
DM (%)	–	32.2	
Dyslipidemia (%)	–	33.2	
Family history for CHD (%)	–	9.7	
History of stroke (%)	–	9.2	
CAD (%)	–	16.9	
LLT drugs			
Statins (%)	–	67.8	
Ezetimibe (%)	–	0.8	
Statins + ezetimibe (%)	–	1.5	
Fibrates (%)	–	1.0	
Supplements (%)	–	0.0	
Primary prevention (%)	–	27.6	
Secondary prevention (%)	–	72.4	
Non-cardiovascular diseases factors			
Asthma (%)	–	9.2	
COPD (%)	–	2.0	
Thrombophlebitis (%)	–	2.6	
Peptic ulcer disease (%)	–	2.4	
Gout (%)	–	10.2	
Osteoporosis (%)	–	7.1	
Rheumatoid arthritis (%)	–	6.8	
Thyroid disease (%)	–	20.0	
Liver disease (%)	–	5.1	
History of cancer disease (%)	–	7.9	
COVID vaccination (%)	63.8	73.4	0.033
Laboratory indices			
hsCRP [mg/l]	2.12 ±2.4	2.35 ±4.7	0.007
Lp(a) [mg/dl]	65.4 ±29	72.7 ±35	0.118
TC [mg/dl]	222.6 ±38	181.7 ±43	< 0.001
LDL-C [mg/dl]	140.5 ±34	103.6 ±43	< 0.001
HDL-C [mg/dl]	59.3 ±12	55.7 ±13	0.071
TG [mg/dl]	116.3 ±61	121.1 ±55	0.526
Non-HDL-C [mg/dl]	166.2 ±35	126.9 ±41	< 0.001
TG/HDL [mg/dl]	2.18 ±1.2	2.41 ±1.4	0.355

Variable	Healthy	Patients	P-value
	(n = 50)	(n = 295)	
Creatinine [μmol/l]	0.79 ±0.15	0.85 ±0.26	0.049
Glucose [mg/dl]	91.8 ±16	104.8 ±31	< 0.001
HbA$_{1c}$ (%)	5.44 ±0.5	5.86 ±0.8	< 0.001
Homocysteine [μmol/l]	12.5 ±4	13.6 ±9	0.247
Folic acid [nmol/l]	8.94 ±4.7	7.33 ±4.2	0.167
Vitamin B12 [pmol/l]	430 ±173	451 ±327	0.332
Vitamin D3 [nmol/l]	42.3 ±22	36.2 ±16	0.048
Ferrum [μmol/l]	104.6 ±43	110.9 ±84	0.617
Ferritin [ng/ml]	127.9 ±91	153.4 ±140	0.309
Transferrin [mg/dl]	2.56 ±0.4	2.63 ±0.4	0.441
TSH [μIU/ml]	1.64 ±0.6	1.63 ±1.5	0.924
Imaging indices			
CAC	43.1 ±99	339.9 ±543	< 0.001
CAC 0 score (%)	82.0	63.1	0.001
CAC 1-99 scores (%)	14.0	12.2	0.191
CAC ≥ 100 scores (%)	4.0	24.7	< 0.001
LV EF (%)	59.8 ±4.4	57.4 ±5.8	0.051
TAPSE [cm]	2.64 ±0.26	2.49 ±0.25	0.013
Aorta [cm]	3.23 ±0.30	3.36 ±0.45	0.077
Contraction abnormalities (%)	13.3	15.6	0.121

Healthy – age > 50 years, Lp(a) ≥ 30 mg, Patients – age > 50 years, Lp(a) ≥ 30 mg/l, CRF ≥ 3, AH – arterial hypertension, BMI – body mass index, CHD – coronary heart disease, CAD – coronary artery disease, DM – diabetes mellitus, HR – heart rate, Lp(a) – lipoprotein a, TC – total cholesterol, LDL-C – low–density lipoprotein cholesterol, HDL-C – high–density lipoprotein cholesterol, TG – total triglyceride, CRP – C-reactive protein, TSH – thyroid stimulus hormone, CAC – coronary artery calcium; LVEF – left ventricle ejection fraction, TAPSE – tricuspid annulus plane systolic excursion.

Table II. Independent predictors of increasing calcium scores in linear regression

| Variable	Healthy Multivariate analysis	P-value	Patients Multivariate analysis	P-value
	β (95% CI)		β (95% CI)	
Age	0.097 (–0.043 to 0.153%)	0.101	0.041 (0.008 to 0.074%)	0.017
Gender	–0.191 (–0.121 to –0.840%)	0.045	–0.334 (–0.880 to –0.221%)	0.225
Obesity	–0.191 (–0.121 to 0.740%)	0.561	0.114 (–0.409 to 0.636%)	0.664
hsCRP	–0.051 (–0.171 to 0.070%)	0.273	–0.017 (–0.052 to 0.018%)	0.350
Vit D	–0.002 (–0.013 to 0.008%)	0.541	0.009 (–0.006 to 0.026%)	0.250
TAPSE	–0.140 (–0.412 to 0.132%)	0.201	–0.043 (–0.057 to 0.143%)	0.394
Non-HDL-C	0.013 (0.001 to 0.035%)	0.023	0.008 (0.002 to 0.014%)	0.046

Healthy – age > 50 years, Lp(a) ≥ 30 mg, Patients – age > 50 years, Lp(a) ≥ 30 mg/l, CRF ≥ 3, hsCRP – high-sensitivity C-reactive protein, TAPSE – tricuspid annulus plane systolic excursion, non-HDL-C – non-high-density lipoprotein cholesterol.

and biochemical variables and CAC scores. Both univariate and multivariate models were applied across the entire study population (Supplementary Table SI) as well as within two sub-groups of healthy individuals and patients with Lp(a) ≥ 30 mg/dl (Table II, Figure 1).

Among healthy individuals, the multivariate regression analysis revealed that non-HDL cholesterol was a significant independent predictor of CAC score (β = 0.013; 95% CI: 0.001–0.035%;

p = 0.023). Gender demonstrated a significant inverse association (β = –0.191, p = 0.045), suggesting lower CAC scores in females. In the sub-group of patients, age (β = 0.041; 95% CI: 0.008–0.074%; p = 0.017) and non-HDL cholesterol (β = 0.008; 95% CI: 0.002–0.014%; p = 0.046) were identified as significant predictors of increased calcium scores. No other variables reached statistical significance in the patient group (Table II, Figure 1).

Bożena Sosnowska, Ibadete Bytyci, Joanna Lewek, Agata Bielecka-Dabrowa, Monika Burzyńska, Piotr Jankowski, Michal Chudzik, Maciej Banach

Figure 1. Independent predictors of atherosclerosis progression in healthy individuals and patients aged > 50 years and Lp(a) ≥ 30 mg/dl based on the data from multivariate linear regression analysis (1), and correlation analyses with CAC score (2) and CRP (3)

Correlation of CAC score with clinical and laboratory variables

To further explore the relationships between CAC scores and selected clinical or biochemical markers, correlation analyses were performed in both sub-groups (Table III, Figure 1). In the patient group, CAC score showed significant positive correlations with age ($r = 0.359$, $p = 0.001$), gender ($r = 0.205$, $p = 0.020$), non-HDL-C ($r = 0.218$, $p = 0.025$), HbA_{1c} ($r = 0.213$, $p = 0.011$), and Lp(a) ($r = 0.132$, $p = 0.033$). Among healthy individuals, CAC score correlated significantly with gender ($r = -0.343$, $p = 0.044$), indicating lower scores in females as well as with obesity ($r = 0.439$, $p = 0.05$) and non-HDL-C ($r = 0.554$, $p = 0.011$), with the latter demonstrating a particularly strong association (Table III, Figure 1).

Correlation of CRP with clinical and laboratory variables

CRP level, inflammation biomarker indicating the risk of atheroma plaque formation [22], was significantly correlated with age ($r = 0.194$, $p = 0.043$), obesity ($r = 0.225$, p = 0.022), and HbA_{1c} ($r = 0.154$, $p = 0.005$), indicating a trend towards significance with Lp(a) ($r = 0.295$, $p = 0.061$) in the patient group. In healthy individuals, signif-

icant correlations were observed between CRP and TSH ($r = 0.376$, $p = 0.008$) as well as obesity ($r = 0.207$, $p = 0.039$), gender ($r = 0.225$, $p = 0.039$), and non-HDL-C ($r = 0.207$, $p = 0.033$) (Table III, Figure 1). Importantly, no correlation was found between CRP and CAC score in either group, supporting the findings from the multivariate regression analysis, which showed that CRP was not an independent predictor for CAC score changes.

Characteristic of healthy individuals and patients with Lp(a) > 50 mg/dL

In the sub-group of participants with high Lp(a) levels (> 50 mg/dl/125 nmol/l), a total of 227 participants, comprising 200 patients and 27 healthy individuals, were included. The univariate and multivariate models for the entire study population are displayed in Supplementary Table SII.

Patients were significantly older (69.2 ±8.7 vs. 62.3 ±8.9 years, $p < 0.001$), and the proportion of females in the patient group was lower (68.5% vs. 77.8%, $p = 0.021$). Lp(a) levels were similar in both groups (88.8 ±32 vs. 87.8 ±21 mg/dl), obesity was more common among patients (31.7% vs. 18.5%, $p = 0.001$), while BMI and heart rate did not differ significantly between the groups (Table IV).

The burden of CVD comorbidities among patients included arterial hypertension (77.5%), di-

Table III. Correlation of CAC and CRP with demographic and laboratory indices among healthy at risk and patients aged > 50 years and Lp(a) ≥ 30 mg/dl

Variable	r	P-value	r	P-value
	Healthy		Patients	
CAC				
Age	0.159	0.261	0.359	0.001
Gender	−0.343	0.044	0.205	0.020
Obesity	0.439	0.050	−0.114	0.116
Non-HDL-C	0.554	0.011	0.218	0.025
hsCRP	0.056	0.699	−0.044	0.596
Vit D	−0.139	0.889	−0.045	0.644
HbA1c	0.279	0.248	0.213	0.011
TAPSE	−0.343	0.091	0.093	0.147
Homocysteine	−0.099	0.802	−0.155	0.817
Lp(a)	0.185	0.431	0.132	0.033
CRP				
Age	0.250	0.054	0.194	0.043
Gender	0.225	0.042	−0.962	0.286
Obesity	0.207	0.039	0.225	0.022
Non-HDL-C	0.207	0.033	0.094	0.160
CAC	0.056	0.699	−0.044	0.596
Vit D	0.133	0.671	0.030	0.633
TSH	0.376	0.008	−0.044	0.455
HbA$_{1c}$	0.270	0.066	0.154	0.005
Homocysteine	0.091	0.774	0.036	0.656
Lp(a)	0.214	0.136	0.295	0.061

Healthy − age > 50 years, Lp(a) ≥ 30 mg, Patients − age > 50 years, Lp(a) ≥ 30 mg/l, CRF ≥ 3, Lp(a) - lipoprotein a, non-HDL-C − non-high-density lipoprotein cholesterol, TSH − thyroid stimulus hormone, CAC- coronary artery calcium, hsCRP − high-sensitivity C-reactive protein, TAPSE − tricuspid annulus plane systolic excursion, HbA1c − glycated hemoglobin A1c.

abetes mellitus (35.0%), dyslipidemia (34.5%), CAD (19.9%), and a history of stroke (7.5%). Statin treatment was reported in 67.4% of patients, whereas combination of lipid-lowering therapy (LLT) was used infrequently (2.2%) (Table IV). In laboratory analyses, patients had significantly better lipid profiles due to baseline treatment (e.g., LDL-C: 105.1 ±45 vs. 154.8 ±34 mg/dl, $p < 0.001$), and significantly higher glucose and HbA$_{1c}$ levels ($p < 0.001$ for both). Vitamin D levels were lower in patients (35.2 ±16 vs. 45.3 ±26 nmol/l, $p = 0.041$). CAC scores were significantly higher in the patient group (328.4 ±572 vs. 53.1 ±116, $p < 0.001$), with a higher proportion of patients with CAC scores ≥ 100 (14% vs. 7.41%, $p = 0.012$), and a lower proportion with the "power of zero" (CAC = 0: 62.5% vs. 74.1%, $p = 0.001$) (Table IV).

Linear regression analysis of healthy individuals and patients with Lp(a) > 50 mg/dl

Among healthy individuals, several factors were significantly associated with CAC scores in univariate analysis (Table V), including gender (β = 0.150, 95% CI: 0.107–0.202%; $p < 0.001$), obesity (β = 0.123; 95% CI: 0.101–0.204%; $p = 0.004$), elevated hsCRP (β = 0.176; 95% CI: 0.102–0.252%; $p < 0.001$), vitamin D levels (β = 1.667; 95% CI: 0.109–0.235%; $p < 0.001$), non-HDL-C (β = 0.201; 95% CI: 0.108–0.320%; $p < 0.001$), and Lp(a) (β = 0.159; 95% CI: 0.101–0.268%; $p = 0.006$). However, in the multivariate model adjusted for potential confounding variables, only two predictors remained statistically significant, including gender (β = 0.106; 95% CI: 0.045–0.203%; $p = 0.037$) and elevated hsCRP (β = 0.104; 95% CI: 0.033–0.489%; $p = 0.013$) (Table V, Figure 2). Notably, Lp(a), despite being highly elevated in all individuals in this sub-group by definition, was not an independent predictor of CAC progression after adjustment (β = −0.017, $p = 0.337$).

In patients, Lp(a) was a significant predictor of CAC score in both univariate (β = 0.110, $p < 0.001$) and multivariate models (β = 0.006; 95% CI: 0.002–0.012%; $p = 0.041$), indicating that Lp(a) > 50 mg/dl independently contributed to calcium score progression in the patient group. Additionally, age re-

Bożena Sosnowska, Ibadete Bytyci, Joanna Lewek, Agata Bielecka-Dabrowa, Monika Burzyńska, Piotr Jankowski, Michal Chudzik, Maciej Banach

Table IV. Demographic, laboratory, and imaging indices among healthy individuals and patients aged > 50 years and Lp(a) > 50 mg/dl

Variable	Healthy	Patients	*P*-value
	(*n* = 27)	(*n* = 200)	
Demographic and clinical indices			
Age [years]	62.3 ±8.9	69.2 ±8.7	< 0.001
Female (%)	77.8	68.5	0.021
BMI [kg/m²]	27.9 ±4.4	28.8 ±5.3	0.409
Overweight (%)	77.8	76.9	0.918
Obese (%)	18.5	31.7	0.001
HR [bpm]	74.9 ±10	73.5 ±11	0.527
Sinus rhythm (%)	100.0	97.2	0.301
Cardiovascular risk factors			
AH (%)	–	77.5	–
DM (%)	–	35.0	–
Dyslipidemia (%)	–	34.5	–
Family history for CHD (%)	–	9.9	–
History of stroke (%)	–	7.5	–
CAD (%)	–	19.9	–
LLT drugs			
Statins (%)	–	67.4	–
Ezetimibe (%)	–	1.1	–
Statins + ezetimibe (%)	–	2.2	–
Fibrates (%)	–	1.0	–
Supplements (%)	–	0.0	–
Primary prevention (%)	–	27.5	–
Secondary prevention (%)	-	72.5	–
Non-cardiovascular diseases factors			
Asthma (%)	–	10.5	–
COPD (%)	–	2.5	–
Thrombophlebitis (%)	–	2.5	–
Peptic ulcer disease (%)	–	2.0	–
Gout (%)	–	10.0	–
Osteoporosis (%)	–	4.4	–
Rheumatoid arthritis (%)	–	7.0	–
Thyroid disease (%)	–	21.0	–
Liver disease (%)	–	4.0	–
History of cancer disease (%)	–	7.3	–
COVID vaccination (%)	64.0	75.9	0.014
Laboratory indices			
hsCRP [mg/l])	2.57 ±2.6	2.38 ±4.9	0.204
Lp(a) [mg/dl]	87.8 ±21	88.8 ±32	0.838
TC [mg/dl]	235.3 ±35	183.1 ±44	< 0.001
LDL-C [mg/dl]	154.8 ±34	105.1 ±45	< 0.001
HDL-C [mg/dl]	57.6 ±11	55.7 ±13	0.479
TG [mg/dl]	115.7 ±54	124.9 ±58	0.416
Non-HDL-C [mg/dl]	177.7 ±38	129.1 ±44	< 0.001
TG/HDL [mg/dl]	2.14 ±1	2.45 ±1.3	0.372

Creatinine [µmol/l]	0.82 ±0.17	0.86 ±0.26	0.452
Glucose [mg/dl]	89.7 ±12	104.7 ±26	< 0.001
HbA$_{1c}$ (%)	5.42 ±0.3	5.88 ±0.8	< 0.001
Homocysteine [µmol/l]	11.8 ±2.9	12.8 ±4.1	0.263
Folic acid [nmol/l]	8.40 ±5.2	7.63 ±4.2	0.663
Vitamin B$_{12}$ [pmol/l]	431 ±144	449 ±193	0.692
Vitamin D$_3$ [nmol/l]	45.3 ±26	35.2 ±16	0.041
Ferrum [µmol/l]	97.6 ±28	107.6 ±83	0.418
Ferritin [ng/ml]	147.3 ±98	152.4 ±153	0.878
Transferrin [mg/dl]	2.52 ±0.5	2.60 ±0.4	0.335
TSH [µIU/ml]	1.65 ±0.9	1.74 ±1.6	0.641
Imaging indices			
CAC	53.1 ±116	328.4 ±572	< 0.001
CAC 0 scores (%)	74.1	62.5	0.001
CAC 1-99 scores (%)	18.5	13.5	0.041
CAC ≥ 100 scores (%)	7.41	14.0	0.012
LV EF (%)	60.4 ±4.6	57.8 ±8.8	0.110
TAPSE [cm]	2.51 ±0.18	2.47 ±0.25	0.532
Aorta [cm]	3.22 ±0.32	3.43 ±0.49	0.821
Contraction abnormalities (%)	7.7	15.6	0.044

Healthy – age > 50 years, Lp(a) > 50 mg, Patients – age > 50 years, Lp(a) > 50 mg/l, CRF ≥ 3, BMI – body mass index, HR – heart rate, AH – arterial hypertension, DM – diabetes mellitus, CAD – coronary artery disease, COPD – chronic obstructive pulmonary disease, hsCRP – high-sensitivity C-reactive protein, Lp(a) – lipoprotein a, TC – total cholesterol, LDL–C – low-density lipoprotein cholesterol, HDL-C – high-density lipoprotein cholesterol, TG – total triglyceride, non-HDL–C – non-high-density lipoprotein cholesterol, HbA1c – glycated hemoglobin A1c, TSH – thyroid stimulus hormone, CAC – coronary artery calcium, LVEF – left ventricle ejection fraction, TAPSE – tricuspid annulus plane systolic excursion.

Table V. Predictors of increasing calcium scores in linear regression in healthy and patients aged > 50 years and Lp(a) > 50 mg/dl

Variable	Univariate	P-value	Multivariate	P-value
	β (95% CI)		β (95% CI)	
Healthy				
Age	0.078 (–0.109 to 0.256%)	0.378		
Gender	0.150 (0.107 to 0.202%)	< 0.001	0.106 (0.045 to 0.203%)	0.037
Obesity	0.123 (0.101 to 0.204%)	0.004	0.007 (–0.119 to 0.133%)	0.865
Elevated hsCRP	0.176 (0.102 to 0.252%)	< 0.001	0.104 (0.033 to 0.489%)	0.013
Vit D	0.166 (0.109 to 0.235%)	< 0.001	–0.008 (–0.032 to 0.016%)	0.371
Homocysteine	0.092 (–0.190 to 0.237%)	0.092		
HbA$_{1c}$	0.607 (0.566 to 1.353%)	0.352		
Non-HDL-C	0.201 (0.108 to 0.320%)	< 0.001	–0.001 (–0.032 to 0.029%)	0.909
Lp(a)	0.159 (0.101 to 0.268%)	0.006	–0.017 (–0.064 to 0.030%)	0.337
Patients				
Age	0.080 (0.013 to 0.124%)	0.025	0.029 (0.004 to 0.053%)	0.021
Gender	0.161 (0.104 to 0.803%)	< 0.001	0.029 (–0.390 to 0.448%)	0.890
Obese	0.164 (0.129 to 0.234%)	< 0.001	–0.225 (–0.681 to 0.230%)	0.881
Elevated hsCRP	0.173 (0.103 to 0.211%)	< 0.001	0.157 (–0.247 to 0.562%)	0.332
Vit D	0.143 (0.107 to 0.179%)	< 0.001	0.011 (–0.563 to 0.033%)	0.061
HbA$_{1c}$	0.110 (0.025 to 0.196%)	< 0.001	0.215 (–0.066 to 0.529%)	0.212
Non-HDL-C	0.155 (0.111 to 0.201%)	< 0.001	–0.002 (–0.007 to 0.009%)	0.119
Lp(a)	0.110 (0.077 to 0.144%)	< 0.001	0.006 (0.002 to 0.012%)	0.041

hsCRP – high-sensitivity C-reactive protein, Lp(a) – lipoprotein a, non-HDL-C – non-high-density lipoprotein cholesterol, HbA$_{1c}$ – glycated hemoglobin A$_{1c}$.

Bożena Sosnowska, Ibadete Bytyci, Joanna Lewek, Agata Bielecka-Dabrowa, Monika Burzyńska, Piotr Jankowski, Michal Chudzik, Maciej Banach

Figure 2. Independent predictors of atherosclerosis progression in healthy individuals and patients aged > 50 years and Lp(a) > 50 mg/dl based on the data from multivariate linear regression analysis (1), and correlation analyses with CAC score (2) and CRP (3)

mained significant ($\beta = 0.029$, $p = 0.021$), whereas other variables, such as obesity, hsCRP, HbA_{1c}, and non-HDL-C did not show independent associations after adjustment (Table V, Figure 2).

Correlation of CAC score with clinical and laboratory variables

In the correlation analysis among healthy individuals with high Lp(a) levels, CAC was positively associated with obesity ($r = 0.592$, $p = 0.026$), LDL-C ($r = 0.647$, $p = 0.011$), non-HDL-C ($r = 0.616$, $p = 0.014$), and hsCRP ($r = 0.294$, $p = 0.048$), while it was negatively associated with gender ($r = -0.321$, $p = 0.045$). Among patients, CAC correlated significantly with age ($r = 0.418$, $p < 0.001$), HbA_{1c} ($r = 0.199$, $p = 0.044$), and Lp(a) ($r = 0.319$, $p = 0.022$) (Table VI, Figure 2).

CRP correlation with clinical and laboratory variables

In healthy individuals, CRP analysis revealed that it correlated with age ($r = 0.333$, $p = 0.031$), gender ($r = -0.251$, $p = 0.048$), LDL-C ($r = 0.225$, $p = 0.034$), and CAC ($r = 0.294$, $p = 0.048$). No correlation was found between CRP and Lp(a) in patients ($p = 0.341$) (Table VI, Figure 2). In the patient group, CRP significantly correlated with age ($r = 0.304$, $p = 0.032$),

obesity ($r = 0.294$, $p = 0.044$), HbA_{1c} ($r = 0.202$, $p = 0.024$), and Lp(a) ($r = 0.195$, $p = 0.038$), suggesting a link between inflammation and Lp(a) in individuals at very high-risk of CVD.

Discussion

The primary objective of this study was to investigate additional risk factors and conditions, which contribute to the progression of ASCVD in individuals with elevated Lp(a), and to identify potential protective or mitigating factors, which may decrease its adverse effects. Our results demonstrate that the relationship between Lp(a) and sub-clinical atherosclerosis, as measured by CAC score (and hsCRP), varies substantially according to baseline metabolic health and cardiovascular risk status. In the overall cohort of adults aged over 50 years with Lp(a) $\geq$ 30 mg/dl, significant univariate associations between Lp(a) and CAC were no longer evident after adjustment for age, non-HDL-C, and other metabolic covariates. This suggests that, at moderately elevated levels, the apparent link between Lp(a) and CAC largely reflects confounding by established cardiometabolic risk factors, rather than an independent causal effect. However, among metabolically healthy individuals without CVD or classical risk factors, CAC burden correlated primarily with inflamma-

Table VI. Correlation of CAC and CRP with demographic and laboratory indices among healthy at risk and patients aged > 50 years and Lp(a) > 50 mg/dl

Variable	r	P-value	r	P-value
	Healthy		Patients	
CAC				
Age	0.123	0.522	0.418	< 0.001
Gender	−0.321	0.045	−0.154	0.120
Obesity	0.592	0.026	−0.117	0.332
LDL-C	0.647	0.011	0.123	0.224
Non-HDL-C	0.616	0.029	0.204	0.074
hsCRP	0.294	0.048	0.186	0.056
Vit D	−0.277	0.446	0.145	0.113
TSH	−0.229	0.260	0.016	0.811
HbA$_{1c}$	0.280	0.125	0.199	0.044
Homocysteine	0.102	0.167	0.092	0.443
Lp(a)	-0.102	0.609	0.319	0.022
CRP				
Age	0.333	0.031	0.304	0.032
Gender	−0.251	0.048	−0.128	0.088
Obesity	0.135	0.502	0.294	0.044
LDL-C	0.225	0.034	0.197	0.066
Non-HDL-C	0.121	0.159	0.048	0.113
CAC	0.294	0.048	0.186	0.056
Vit D	0.289	0.301	0.024	0.795
TSH	0.180	0.337	0.035	0.162
HbA$_{1c}$	−0.155	0.474	0.202	0.024
Homocysteine	0.151	0.113	0.071	0.097
Lp(a)	0.212	0.341	0.195	0.038

LDL-C – low–density lipoprotein cholesterol, non-HDL-C – non-high-density lipoprotein cholesterol, hsCRP – high-sensitivity C-reactive protein, TSH – thyroid stimulus hormone, HbA1c – glycated hemoglobin A1c, Lp(a) – lipoprotein a, CAC – coronary artery calcium.

tory status (observed in obese individuals) and lipid parameters (non-HDL-C), whereas Lp(a) itself was not an independent determinant. Conversely, in the patient group, Lp(a) correlated significantly with CAC even after multivariable adjustment, alongside other established CVD risk factors, such as non-HDL-C and elevated HbA$_{1c}$. It is also worth emphasizing the differences in non-modifiable CVD risk factors between the groups, with gender predominating in the healthy cohort and age in the patient group. These findings were confirmed when analyzing healthy individuals and patients aged over 50 years with Lp(a) > 50 mg/dl. Lp(a) was an independent risk factor for atherosclerosis progression only in the patient group. Gender and age as non-modifiable risk factors differentiated the groups, whereas in generally healthy subjects, more classical factors, such as elevated hsCRP and LDL C, significantly increased the risk of atherosclerosis progression.

HsCRP is a well-established biomarker of systemic inflammation, widely used in CVD risk as-

sessment [23]. Several large observational studies have explored whether inflammatory status modifies the cardiovascular risk conferred by elevated Lp(a). Findings from Small *et al.* [24] and Thomas *et al.* [25] studies indicate that Lp(a) predicts CVD events independently of hsCRP in both primary and secondary prevention populations. In contrast, Arnold *et al.* [26], using the BiomarCaRE cohort, found that in individuals without coronary heart disease (CHD) at baseline, the association between Lp(a) and incident CHD was independent of hsCRP, whereas in patients with established CHD, Lp(a) was related to recurrent events only in those with elevated hsCRP, suggesting that inflammation may amplify Lp(a) -mediated risk in secondary prevention. In line with this, data from the MESA (multi-ethnic study of atherosclerosis) study [27] reported that Lp(a) -associated ASCVD risk was more pronounced when hsCRP was concurrently elevated, supporting the "second-hit" hypothesis whereby systemic inflammation potentiates the pathogenic impact of Lp(a). On

the contrary, a large meta-analysis by Albena *et al.* [28], including over 560,000 participants, showed that elevated Lp(a) increased major adverse cardiovascular event (MACE) risk regardless of hsCRP, underscoring the multifactorial nature of its atherogenic effects. Our analysis in adults over 50 years of age with elevated Lp(a) indicates that Lp(a) was independently associated with atherosclerosis progression (assessed by CAC score) only in the patient group, whereas hsCRP independently increased the risk of atherosclerosis progression in the healthy group only.

Coronary artery calcification is a robust surrogate marker of total atherosclerotic plaque burden, and an established tool for refining CVD risk stratification [29]. In the MESA study [30], both Lp(a) and CAC independently predicted ASCVD events, with the highest risk observed in individuals with both elevated Lp(a) and CAC > 100. Notably, previous analysis of the entire STAR-Lp(a) cohort [31] demonstrated a positive association between Lp(a) concentration and CAC score: per 10 mg/dl (25 nmol/l) increase in Lp(a), CAC score increased by 15.7 (p = 0.006). The present sub-analysis extends these findings by showing that this relationship is not uniform across risk strata; in metabolically healthy individuals, even with high level of Lp(a), the significant association is weak or does not exist after adjusting for age, inflammation, and lipids, whereas in high-risk patients, Lp(a) remains a strong, independent determinant of coronary calcification. Our findings somewhat align with data from the MESA study and the Dallas Heart Study (DHS) [32] as well as emerging evidence from the UK Biobank [17], which demonstrate a general association between elevated Lp(a) concentrations and increased ASCVD risk, although its specific relationship with CAC is less consistent. For example, in the MESA study, elevated Lp(a) was more strongly associated with non-calcified plaque characteristics than with CAC burden, highlighting that calcification may not fully capture the atherogenic effects of Lp(a). Similarly, Sung *et al.* [33] conducted a large imaging study in asymptomatic adults, and found that Lp(a) ≥ 50 mg/dl was not associated with CAC incidence or progression over time, reinforcing the concept that elevated Lp(a) does not necessarily manifest as increased coronary calcification in low-risk populations. The cohort in our analysis, including cases in secondary prevention, was largely pre-event, with > 60% demonstrating the "power of zero" (CAC = 0) and only 15–25% having CAC > 100.

Further mechanistic insight can be found in the PROSPECT II sub-study by Erlinge *et al.* [19], which used intracoronary imaging to characterize plaque morphology. This study showed that Lp(a) was not associated with total plaque burden, but was selectively linked to vulnerable, rupture-prone plaques rich in necrotic core and lipid content (i.e., the higher CVD risk, the stranger association). This aligns with the hypothesis that Lp(a) may exert its deleterious effects primarily by promoting plaque instability, rather than calcification per se. The association between Lp(a) and atherosclerosis observed in our data (only in the very high-risk group of patients) may therefore be also explained by several non-atherosclerotic mechanisms through which Lp(a) increases ASCVD risk, including potential pro-thrombotic and pro-platelet effects as well as vascular inflammation mediated by oxidized phospholipids (OxPLs) [34]. OxPLs carried by the apo (a) moiety may be particularly important contributors to the development of non-calcified, high-risk plaques and to acute coronary events [35].

The inflammatory-metabolic modulation of Lp(a)-associated risk observed in our study corresponds to findings from Mohammadnia *et al.* [36], who in a secondary prevention cohort demonstrated that interleukin-6 (IL-6) amplifies the atherogenic effects of Lp(a) -bound OxPLs. Elevated IL-6 levels were associated with a greater hazard of CVD events, indicating that inflammation acts as a "second hit" required for Lp(a) -driven atherothrombosis. In our cohort, a similar pattern emerged, i.e., Lp(a) was independently associated with CAC only in high-risk patients, whereas in healthy individuals, even in those with very high Lp(a), its effect was attenuated after adjusting for hsCRP and metabolic parameters. This supports the concept that Lp(a) -associated cardiovascular risk is not fixed, but dynamically influenced by inflammatory status and metabolic health.

The potential for lifestyle and behavioral factors to modify Lp(a) -related risk was further illustrated by Razavi *et al.* [37], who examined over 6,600 asymptomatic individuals, 20% of whom had Lp(a) ≥ 50 mg/dl. They found that an optimal American Heart Association (AHA) Life's Simple 7 (LS7) cardiovascular health score was associated with a 65% reduction in ASCVD events (HR = 0.35; 95% CI: 0.13–0.99), regardless of Lp(a) concentration. This supports the growing consensus that elevated Lp(a) does not inevitably lead to clinical disease, and that favorable metabolic, lifestyle, and inflammatory conditions can substantially mitigate its pathogenic potential. Nonetheless, everyone should know own Lp(a) level; for this reason, Lp(a) is now included in the recently released International Lipid Expert Panel SiMple tIps for the heaLthy hEart (ILEP-SMILE) algorithm [38].

From a broader epidemiological perspective, our findings refine the conclusions of Bhatia *et al.* [39], whose meta-analysis across multiple cardiovascular outcome trials concluded that Lp(a) confers cardiovascular risk independently of LDL-C, justifying the development of targeted therapies. While Bhatia et al. focused on clinical

events, such as myocardial infarction and stroke, our study evaluated sub-clinical calcific atherosclerosis, which may represent a late or distinct phase of vascular re-modeling. These findings may also have important clinical implications in the context of the current European Society of Cardiology (ESC) and Polish recommendations [40, 41]. At present, no pharmacologically approved agents are available for routine lowering of Lp(a), although targeted therapies, such as antisense oligonucleotides and small interfering RNA, are employed in advanced stages of clinical development [42, 43]. Consequently, the management of individuals with elevated Lp(a) should focus on aggressive optimization of all other modifiable CVD risk factors, including strict control of blood pressure, LDL-C and non-HDL-C (using high-intensity statins and [upfront] combination therapy as indicated in [44–46]), glycemic status, body weight, and systemic inflammation [41]. Our results reinforce the importance of the following strategy: in metabolically healthy individuals, even those with markedly elevated Lp(a), the absence of additional cardiometabolic stressors appears to substantially attenuate the atherogenic potential of Lp(a), whereas in those with concurrent metabolic or inflammatory risk factors, Lp(a) emerges as an independent driver of coronary artery calcification. These observations underscore the value of early and sustained preventive interventions initiated well before the disease develops overtly, which maintain metabolic balance, promote healthy weight, and suppress low-grade inflammation. Such measures may represent the most effective means currently available to mitigate Lp(a) -related risk, until targeted Lp(a) -lowering therapies become clinically accessible.

One important limitation is the non-randomized, selection-based study design, in which patients with and without cardiovascular risk factors were deliberately recruited into separate groups. While this approach supports hypothesis generation and comparative profiling, it limits causal inference. Therefore, our findings should be interpreted as descriptive and exploratory, rather than definitive proof of risk or protection. The number of participants, especially in the healthy group, may also be considered a limitation.

In conclusion, although Lp(a) is recognized as a strong and independent CVD risk factor in large-scale studies, our findings based on RWE data suggest that its role in promoting vascular calcification is conditional and context-dependent. Among healthy individuals, even with elevated Lp(a), CAC progression was more closely related to traditional risk factors, such as gender, non-HDL cholesterol, obesity, and low-grade inflammation (hsCRP). In this group, Lp(a) was not

an independent predictor of calcification and did not correlate with CAC in multivariable analysis. In contrast, among patients, especially in those with Lp(a) > 50 mg/dl, Lp(a) emerged as a significant and independent predictor of coronary calcification, indicating that its pro-atherogenic effects are likely amplified by the presence of additional metabolic or inflammatory disturbances.

These findings support a multifactorial model of atherosclerosis, in which Lp(a) acts as a potentiator of risk in already vulnerable vascular environments, rather than as a dominant, standalone driver of calcification. Taken together, our results highlight the importance of individual cardiovascular risk profiling when interpreting elevated Lp(a) levels. Optimally targeting coexisting modifiable factors, such as lipid abnormalities, inflammation, and glucose metabolism, as early as possible, may offer effective strategies to mitigate the vascular risk posed by high Lp(a) concentration, particularly in primary prevention.

Acknowledgments

Funding

Ethical approval

The study was approved by the Bioethics Committee of Lodz Regional Medical Chamber (approval number: K.B.-0115/2021). Informed consent was obtained from all patients.

Conflict of interest

Maciej Banach: speakers bureau: Amgen, Adamed, Daiichi Sankyo, KRKA, Polpharma, Mylan/Viatris, MSD, Novartis, Novo-Nordisk, Pfizer, Sanofi, Teva, Zentiva; consultant to Adamed, Amgen, Daiichi Sankyo, Esperion, NewAmsterdam, Novartis, Novo-Nordisk, Sanofi, Teva; Grants from Amgen, Daiichi Sankyo, Viatris, Sanofi, and Teva.

All other authors have no conflicts of interest to declare.

References

1. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res 2016; 57: 1339-59.
2. Koschinsky ML, Kronenberg F. The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target. Atherosclerosis 2022; 349: 1-6.
3. Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res 2016; 57: 745-57.

Bożena Sosnowska, Ibadete Bytyci, Joanna Lewek, Agata Bielecka-Dabrowa, Monika Burzyńska, Piotr Jankowski, Michal Chudzik, Maciej Banach

4. Tsimikas S, Witztum JL. Oxidized phospholipids in cardiovascular disease. Nat Rev Cardiol 2024; 21: 170-91.

5. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 52-60.

6. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013; 368: 503-12.

7. Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol 2019; 74: 54-66.

8. Masson W, Lobo M, Barbagelata L, Molinero G, Bluro I, Nogueira JP. Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: a systematic review. Vasc Med 2022; 27: 385-91.

9. Lewek J, Sosnowska B, Bielecka-Dąbrowa A, Mierczak K, Adach W, Banach M. Lipoprotein(a) and other risk factors in dyslipidemic patients with and without heart failure. Arch Med Sci 2024; 20: 1705-9.

10. Dyrbuś K, Mędrala Z, Konsek K, et al. Lipoprotein(a) and its impact on cardiovascular disease - the Polish perspective: design and first results of the Zabrze-Lipoprotein(a) Registry. Arch Med Sci 2024; 20: 1069-76.

11. Björnson E, Adiels M, Taskinen MR, et al. Lipoprotein(a) is markedly more atherogenic than LDL. J Am Coll Cardiol 2024; 83: 385-95.

12. Marston NA, Melloni GEM, Murphy SA, et al. Per-particle cardiovascular risk of lipoprotein(a) vs non-Lp(a) apolipoprotein B-containing lipoproteins. J Am Coll Cardiol 2024; 83: 470-2.

13. Tsimikas S, Bittner V. Particle number and characteristics of lipoprotein(a), LDL, and apoB. J Am Coll Cardiol 2024; 83: 396-400.

14. Clarke SL, Huang RDL, Hilliard AT, et al. Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol. Eur J Prev Cardiol 2025; 32: 116-27.

15. Rocha VZ, Santos RD. The mysterious lipoprotein(a): moving towards further understanding of its atherogenic role. Eur J Prev Cardiol 2025; 32: 128-30.

16. Sosnowska B, Toth PP, Razavi AC, Remaley AT, Blumenthal RS, Banach M. 2024: The year in cardiovascular disease - the year of lipoprotein(a) – research advances and new findings. Arch Med Sci 2025; 21: 355-73.

17. Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a Large National Biobank. Arterioscler Thromb Vasc Biol 2021; 41: 465-74.

18. Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE. Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women. N Engl J Med 2024; 391: 2087-97.

19. Erlinge D, Tsimikas S, Maeng M, et al. Lipoprotein(a), cholesterol, triglyceride levels, and vulnerable coronary plaques. J Am Coll Cardiol 2025; 85: 2011-24.

20. Burzyńska M, Jankowski P, Babicki M, Banach M, Chudzik M. Prevalence of hyperlipoproteinemia(a) in individuals of European ancestry treated at outpatient cardiology clinics: results from a cross-sectional STAR-Lp(a) study. Pol Arch Intern Med 2024; 134: 16860.

21. Bielecka-Dabrowa A, Kapusta J, Sakowicz A, Banach M, Jankowski P, Chudzik M. The influence of long COVID on the cardiovascular system and predictors of long COVID in females: data from the Polish Long COVID Cardiovascular (PoLoCOV-CVD) Study. J Clin Med 2024; 13: 7829.

22. Su M, Zhao W, Jiang H, et al. Endothelial IGFBP6 suppresses vascular inflammation and atherosclerosis. Nat Cardiovasc Res 2025; 4: 145-62.

23. Ridker PM. A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol 2016; 67: 712-23.

24. Small AM, Pournamdari A, Melloni GEM, et al. Lipoprotein(a), C-reactive protein, and cardiovascular risk in primary and secondary prevention populations. JAMA Cardiol 2024; 9: 385-91.

25. Thomas PE, Vedel-Krogh S, Kamstrup PR, Nordestgaard BG. Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein. Eur Heart J 2023; 44: 1449-60.

26. Arnold N, Blaum C, Goßling A, et al. C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project. Eur Heart J 2024; 45: 1043-54.

27. Zhang W, Speiser JL, Ye F, et al. High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a). J Am Coll Cardiol 2021; 78: 1083-94.

28. Alebna PL, Han CY, Ambrosio M, et al. Association of lipoprotein(a) with major adverse cardiovascular events across hs-CRP. JACC Adv 2024; 3: 101409.

29. Chung YH, Lee BK, Kwon HM, et al. Coronary calcification is associated with elevated serum lipoprotein (a) levels in asymptomatic men over the age of 45 years: a cross-sectional study of the Korean national health checkup data. Medicine (Baltimore) 2021; 100: e24962.

30. Mehta A, Vasquez N, Ayers CR, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol 2022; 79: 757-68.

31. Burzynska M, Babicki M, Banach M, Jankowski P, Chudzik M. Lipoprotein(a) as a predictive marker of coronary artery calcification (CAC). The results from the STAR-Lp(a) cohort study. Eur Heart J 2024; 45 (Suppl 1): ehae666.2829.

32. Mehta A, Vasquez N, Ayers CR, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol 2022; 79: 757-68.

33. Sung DE, Rhee EJ, Lee JY, Lee MY, Sung KC. Elevated lipoprotein(a) is not linked to coronary artery calcification incidence or progression. Eur J Prev Cardiol 2025; 32: 746-55.

34. Van Der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation 2016; 134: 611-24.

35. Fras Z, Tršan J, Banach M. On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management. Arch Med Sci 2020; 17: 954-64.

36. Mohammadnia N, Van Broekhoven A, Bax WA, et al. Interleukin-6 modifies lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort. Atherosclerosis 2025; 405: 119211.

37. Razavi AC, Reyes MP, Wilkins JT, et al. Traditional risk factors, optimal cardiovascular health, and elevated lipoprotein(a). Eur J Prev Cardiol 2025; 32: 724-32.

38. Banach M, Fogacci F, Atanasov AG, et al.; International Lipid Expert Panel (ILEP). A 360° perspective on cardiovascular prevention: the International Lipid Expert Panel SiMple tIps for the heaLthy hEart (ILEP-SMILE). Arch Med Sci 2025; 21: 711-8.

39. Bhatia HS, Wandel S, Willeit P, et al. Independence of lipoprotein(a) and low-density lipoprotein cholesterol–mediated cardiovascular risk: a participant-level meta-analysis. Circulation 2025; 151: 312-21.

40. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43: 3925-46.

41. Sosnowska B, Stepinska J, Mitkowski P, et al. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels. Arch Med Sci 2024; 20: 8-27.

42. Sosnowska B, Surma S, Banach M. Targeted treatment against lipoprotein (a): the coming breakthrough in lipid lowering therapy. Pharmaceuticals 2022; 15: 1573.

43. Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Lp(a)-lowering agents in development: a new era in tackling the burden of cardiovascular risk? Pharmaceuticals (Basel) 2025; 18: 753.

44. Banach M, Reiner Ž, Surma S, et al.; International Lipid Expert Panel (ILEP). 2024 Recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the International Lipid Expert Panel (ILEP). Drugs 2024; 84: 1541-77.

45. Banach M, Jaiswal V, Ang SP, et al.; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP). Impact of lipid-lowering combination therapy with statins and ezetimibe vs statin monotherapy on the reduction of cardiovascular outcomes: a meta-analysis. Mayo Clin Proc 2025:S0025-6196(25)00075-8. doi: 10.1016/j.mayocp.2025.01.018.

46. Banach M, Surma S, Guzik TJ, et al. Upfront lipid-lowering combination therapy in high cardiovascular risk patients: a route to effective atherosclerotic cardiovascular disease prevention. Cardiovasc Res 2025; 121: 851-9.